Icon

LETAIRIS (nda022081)- (5MG,10MG)

AMBRISENTAN GILEAD
5MG,10MG
Yes No
2031-Oct-14 2012-Jun-15
2014-Jun-15 None
None No
Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):  To improve exercise ability and delay clinical worsening.  In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
9 0 9
Total Other Developers 2
Drugs with Suitability No
5MG ** ** - - -
10MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 8
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** **** *** ****** ****** ******* ******* *********** **** **. **-*-*, ***** ** ***** ********** ******, *****, ********, *** ******, ***** (***) ***
****** ********** **** *** ********** ************, *** *********** **** ******** *****, ********, ************ (**) *****, ****** ****** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** ****** **. ***, *** *** ***, ******* ***** *. *. **. ** *******-*******, ******-****** *********, *********, ******* ******, ***** (***) ***
****** ***** ***** ******* *********** **** **. *-*, *-**, *-** *** *-**/*/*, ********** ********** ****, ******, *********** ******, ***** (***) ***
****** ***** ***** ******* *** *********** **** **. *-*, *-**, *-** *** *-**/*/*, ********** ********** ****, ******, *********** ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ****** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ********* ****** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.